Internal Reference Number: FOI_6430
Date Request Received: 13/01/2022 00:00:00
Date Request Replied To: 04/02/2022 00:00:00
This response was sent via: By Email
Request Summary: Rheumatology Meds
Request Category: Companies
| Question Number 1: Could you provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 1: Abatacept 44 Adalimumab Humira 26 Adalimumab Biosimilars 222 Apremilast 0 Baricitinib 72 Certolizumab 41 Etanercept Enbrel 10 Etanercept biosimilars 115 Filgotinib 14 Golimumab 24 Guselkumab 0 Infliximab Remicade 8 Infliximab biosimilars 26 Ixekizumab 27 Risankizumab 0 Rituximab Mabthera 0 Rituximab biosimilars 23 Sarilumab 1 Secukinumab 17 Tocilizumab 45 Tofacitinib 30 Upadacitinib 30 Ustekinumab 6 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
